PharmassetX
pharmassetx.com
Actively hiring
Health Care
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$150k
2 rounds on record
Latest round
$100k
Convertible Note · Apr 2026 · 5 mo ago
The money's age
Fresh money
5 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 30
Raised a round Convertible Note $100k · SEC Form D
Sep 10, 2025
Raised a round Convertible Note $50k · SEC Form D
2024
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Convertible Note | Apr 2026 | $100k | — | SEC Form D |
| Convertible Note | Sep 2025 | $50k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | PharmassetX Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Terry MintonExecutive Officer, DirectorSEC Form D
David McClureExecutive Officer, DirectorSEC Form D
Gerald DrydenExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
US FDA Grants Orphan Drug and Rare Pediatric Disease Designations to GEn1E Lifesciences' Dual Signal Modulator for the Treatment of…
Non-invasive, At-home Ultrasound Neuromodulation for Chronic Inflammatory Disorders.
Citryll is pioneering treatments for immune-mediated inflammatory diseases targeting Neutrophil Extracellular Traps with CIT-013.
A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the…
Cadenza Bio is a preclinical biotechnology company focused on developing a series of novel small-molecule drugs for the treatment of…
Pano is a platform biotech venture focused on the clinical development of patented small molecule drugs targeting mitochondrial ion…
Overview
Transforming Treatment for Chronic Inflammatory Diseases. A Patented, FDA-Designated Orphan Drug Targeting Pouchitis and Beyond.
People
Terry Minton
Executive Officer, Director
David McClure
Executive Officer, Director
Gerald Dryden
Executive Officer, Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Louisville
United States
HQ